Kenya Licensed to Produce New HIV Prevention Pill
The agreement allows for generic manufacturing of alimatravir for distribution across 129 countries.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Should countries prioritize local manufacturing of essential medical supplies to improve access and supply chain stability?
Kenya has secured a license to manufacture alimatravir, a new monthly HIV-prevention pill. The project, which is currently in the late-stage research phase, aims to improve medical supply chain autonomy in Africa.
Why it matters
This initiative seeks to address regional health inequities by securing immediate access to preventative medicine in developing countries. The deal prioritizes local manufacturing to reduce reliance on external supply chains.
The drug alimatravir demonstrated in trials that it provides HIV protection within one hour of ingestion. The current production roadmap covers 129 low- and middle-income countries with an estimated cost of $5 per person annually.
The players
Merck
A global pharmaceutical company that manages the intellectual property and licensing for alimatravir.
The Universal Corporation
A Kenyan manufacturing firm selected to produce the drug locally for the African market.
Bill and Melinda Gates Foundation
A global philanthropic organization focused on health research and the scaling of medical access in developing nations.
Unitaid
An international health agency that provides funding and technical support for diagnostic and treatment development.
The details
The initiative utilizes seven selected generic drugmakers to produce the medication, with Unitaid providing technical support to three dedicated African manufacturing facilities. Alimatravir acts as a monthly preventative measure, with recent trials evaluating its performance as a prophylactic agent. This shift to local production is supported by an initial $100 million investment from the Bill and Melinda Gates Foundation.
Timeline
Clinical studies began last year in Uganda, Kenya, and South Africa.
Merck announced the licensing of seven generic drugmakers on Friday.
Clinical trial results are expected next year.
The Tech Race
This project represents a significant shift toward regional manufacturing autonomy in the global race to provide low-cost HIV prevention. It follows the precedent of regional health initiatives aimed at decentralizing production to improve supply chain resilience.
The drug is not yet available to the public and remains in the clinical research phase. Once deployed, the medication is designed to provide protection starting one hour after ingestion for patients in 129 supported countries.
The takeaway
This licensing deal highlights the growing influence of decentralized pharmaceutical production in global health. Stakeholders should track the release of clinical trial results next year to determine the speed of the planned rollout.
What happens next
Clinical trial results for alimatravir are scheduled for release next year, which will inform the next phase of the $80 million market delivery investment by the Bill and Melinda Gates Foundation.
Further reading
For more on the latest research and production shifts, visit Biotech.
Source note: This article includes information reported by Nation.
Live Poll
Should countries prioritize local manufacturing of essential medical supplies to improve access and supply chain stability?
